Author

Tyler Hycner

Observed name: T. Hycner

Institution: University of Chicago Medical Center

Observed institutions: University of Chicago, University of Chicago Medical Center, Bristol-Myers Squibb (United States)

OpenAlex ID: A5041170137

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

2020 · Jagoda K. Jasielec, Tadeusz Kubicki, et al. · Blood · 74

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

2019 · Andrzej J. Jakubowiak, Jagoda K. Jasielec, et al. · British Journal of Haematology · 69

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

2017 · Andrzej Jakubowiak, Noopur Raje, et al. · Blood · 10

Ps1371 Elotuzumab in Combination With Carfilzomib, Lenalidomide, and Dexamethasone (krd) in Patients With Newly Diagnosed Multiple Myeloma (ndmm): a Phase 2 Mmrc Trial

2019 · J. Jasielec, B. Derman, et al. · HemaSphere · 1

Works count: 4

Citation count: 154

H-index: 3

I10-index: 3